Yamada: Raised target price of China Biologic Products (01177.HK) to 10 Hong Kong dollars, maintaining "buy" rating.

According to the Wise Stock Finance app, Daiwa Securities released a research report stating that it maintains a "buy" rating on China Biopharmaceuticals (01177.HK), with the target price raised from 5.6 Hong Kong dollars to 10 Hong Kong dollars based on cash flow discounted rate. Daiwa also raised the company's revenue forecast for 2025 to 2027 by 1% to 6%, and the earnings per share forecast by 56% to 106%, reflecting an upward revision of sales forecasts for innovative drugs, as well as upward revisions of other income forecasts (due to the assumption of continued dividend income from Sinovac Biotech).